Proxy Biomedical recently announced Proxy Bio-XT, a strength reinforcing technology that offers a solution to developers of next generation resorbable orthopaedic products. The proprietary processing technology optimizes the microstructure of biomaterials to enable greater than 100% strength gain in resorbable implantables using the same resorbable material grades as those used in current products.
By achieving strength and toughness increases, Bio-XT can facilitate disruptive innovations in implant design, including:
- Introduction of stronger resorbable products for new indications, for which only non-resorbable products are currently considered suitable.
- Introduction of highly porous products, facilitating osteo-conductivity for higher quality tissue regeneration, without compromising product strength.
- Introduction of lower profile products compared to currently available resorbable products, using less material, without compromising product strength.
“Resorbable implants present a number of clinical benefits for orthopaedic applications but their relatively low inherent strength presents a barrier to new product design and limits the adoption of resorbables in new indications,” said Kieran Moloney, VP of engineering, Proxy Biomedical. “Proxy Bio-XT presents an excellent opportunity to substantially improve the performance of the resorbable implants that are currently on the market.”
Performance gains resulting from Proxy Bio-XT are enabled through maximization of the biomaterials’ inherent mechanical properties, which are compromised during standard processes such as injection molding and extrusion. Results conclusively indicate that resorbable implants manufactured using Bio-XT were significantly stronger than predicate devices of identical geometry and material grade, with a torsional strength increase of 102%, said Proxy Biomedical.
Bio-XT can be applied to any resorbable polymer or biocomposite blend, enabling its use for improvements to existing product families which leverage material grades that are well understood by the clinical and regulatory community.